Scientific Papers

JOURNAL OF INTERNATIONAL STUDIES


© CSR, 2008-2019
ISSN: 2306-3483 (Online), 2071-8330 (Print)

2.8
2019CiteScore
 
83nd percentile
Powered by  Scopus



Directory of Open Access Journals (DOAJ)


Strike Plagiarism

Partners
  • General Founder and Publisher:

    SCImago Journal & Country Rank

  • Publishing Partners:

     


    The journal is co-financed in the years 2022-2024 by the Ministry of Education and Science of the Republic of Poland in the framework of the ministerial programme “Development of Scientific Journals” (RCN) on the basis of contract no. RCN/SN/0669/2021/1 


    University of Szczecin (Poland)

    Academy of Economic Studies in Bucharest (Romania)


     

    Széchenyi István University (Hungary)


     

  • Membership:

     

    Society for Scholarly Publishing (SSP)

    CrossRef

     

R&D accounting treatment, firm performance, and market value: Biotech firms case study

Vol. 12, No 2, 2019

 

Namryoung Lee

 

School of Business, Korea Aerospace University,

South Korea

nrlee@kau.ac.kr

R&D accounting treatment, firm performance, and market value: Biotech firms case study

 

 

 

 

 

Abstract. This study examines the correlation between R&D accounting treatment and market value in association with the firm’s performance, with a focus on biotech firms. Firstly, the results of the analysis show that capitalized R&D has a positive correlation with market value, consistent with existing literature. In the case of biotech firms, capitalized R&D has a higher value relevance compared to other industries. Secondly, this study examines the effect of a decrease in capitalized R&D on market value. It is found that the decrease in capitalized R&D has a negative effect on market value, however, this is not the case for biotech firms. In particular, in years where major biotech firms acknowledge and correct their accounting error, capitalized R&D decrease seems to have a more positive effect on market value. Additionally, this study extends the inquiry in association with the company performance and finds the decrease in capitalized R&D has a significant positive association with market value when the firms get better performance. But when the firm’s performance gets worse, a decrease in capitalized R&D adversely affects the market value. However, this is not the case for biotech firms, suggesting excessive expectation around the R&D process of biotechnology firms.

 

 

Received: August, 2018

1st Revision: December, 2018

Accepted: May, 2019

 

DOI: 10.14254/2071-8330.2019/12-2/4

 

JEL ClassificationM41, G32

KeywordsR&D accounting treatment, decrease in R&D capitalization, biotech, market value